Abstract
Protein-based therapeutics has become one of the most rapidly growing and successful drug class in the clinic. However, there are still a number of key challenges that need to be addressed before the full therapeutic potential of protein drugs can be realized. Of note, many biologically active proteins have very short in vivo half-lives, a fact that has greatly hindered their clinical applications. Consequently, several different strategies including polyethylene glycol modification and fusion with Fc or albumin have been developed and implemented to prolong the serum half-life of protein therapeutics. Here we will focus on the recent advances in the development of Fc-based antibody fragments and domains and their potential use as novel half-life-extending fusion partners for protein therapeutics.
Keywords: Antibody fragments, protein therapeutics, FcRn, half-life, IgG1 Fc, IgG1 CH2, IgG1 CH3.
Current Pharmaceutical Biotechnology
Title:New Directions for Half-Life Extension of Protein Therapeutics: The Rise of Antibody Fc Domains and Fragments
Volume: 17 Issue: 15
Author(s): Lili Wang and Tianlei Ying
Affiliation:
Keywords: Antibody fragments, protein therapeutics, FcRn, half-life, IgG1 Fc, IgG1 CH2, IgG1 CH3.
Abstract: Protein-based therapeutics has become one of the most rapidly growing and successful drug class in the clinic. However, there are still a number of key challenges that need to be addressed before the full therapeutic potential of protein drugs can be realized. Of note, many biologically active proteins have very short in vivo half-lives, a fact that has greatly hindered their clinical applications. Consequently, several different strategies including polyethylene glycol modification and fusion with Fc or albumin have been developed and implemented to prolong the serum half-life of protein therapeutics. Here we will focus on the recent advances in the development of Fc-based antibody fragments and domains and their potential use as novel half-life-extending fusion partners for protein therapeutics.
Export Options
About this article
Cite this article as:
Wang Lili and Ying Tianlei, New Directions for Half-Life Extension of Protein Therapeutics: The Rise of Antibody Fc Domains and Fragments, Current Pharmaceutical Biotechnology 2016; 17 (15) . https://dx.doi.org/10.2174/1389201017666160823144032
DOI https://dx.doi.org/10.2174/1389201017666160823144032 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effects of a New Exclusion Diet on Symptoms and Weight of Patients with Diet-Related Immune-Pathologies
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) A Review on Secure Routing Protocols for Wireless Sensor Networks
International Journal of Sensors, Wireless Communications and Control Metabolic Syndrome X is a Low-Grade Systemic Inflammatory Condition with its Origins in the Perinatal Period
Current Nutrition & Food Science Longitudinal Molecular Imaging of Burn Wound Healing: Effect of Staphylococcus aureus, or Lack of Tumor Necrosis Factor (TNF) or Interleukin-6 (Il-6)
Current Molecular Imaging (Discontinued) Editorial
Recent Patents on CNS Drug Discovery (Discontinued) ACE2 as a Key Target for Treatment of COVID-19 Related Cardiovascular Diseases: Current Progress and Prospect
Current Drug Targets Balaglitazone: A Second Generation Peroxisome Proliferator-Activated Receptor (PPAR) Gamma (γ) Agonist
Mini-Reviews in Medicinal Chemistry Progesterone/Progestagens to Prevent Preterm Birth: When and How
Current Women`s Health Reviews Comparison of Influence of Gamma Rays and E-beam on Some Chloramphenicol Derivatives
Current Analytical Chemistry Structure-Based Virtual Ligand Screening: Recent Success Stories
Combinatorial Chemistry & High Throughput Screening Quantification, Microbial Contamination, Physico-chemical Stability of Repackaged Bevacizumab Stored Under Different Conditions
Current Pharmaceutical Biotechnology Dyslipidemia, Vascular Atheroma and Statins
Current Vascular Pharmacology Histone Acetylation as a Potential Therapeutic Target in Motor Neuron Degenerative Diseases
Current Pharmaceutical Design Microbubbles as Drug Delivery Systems in Cerebrovascular Diseases
Recent Patents on Cardiovascular Drug Discovery The Current Status and Future Perspectives of Studies of Cannabinoid Receptor 1 Antagonists as Anti-Obesity Agents
Current Topics in Medicinal Chemistry Targeting the Noradrenergic System in Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis of Prazosin Trials
Current Drug Targets Chemical Constituents and Biological Activities of Cordia myxa L.: A Review
The Natural Products Journal Long-Term Effectiveness and Safety Outcomes in HIV-1-Infected Patients After a Median Time of 6 Years on Nevirapine
Current HIV Research Combination of Thiazide Diuretics and Angiotensin Receptor Blockers Attenuates Osteoporosis in Hypertensive Rats
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Mechanisms of Liver Injury: An Overview
Current Molecular Medicine